Insight Molecular Diagnostics (IMDX) Cash & Current Investments (2015 - 2026)

Insight Molecular Diagnostics (IMDX) has 12 years of Cash & Current Investments data on file, last reported at $28.9 million in Q1 2026.

• Quarterly Cash & Current Investments fell 6.68% year-over-year to $28.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.9 million (down 6.68% YoY) and the FY2025 annual result came in at $12.3 million, up 42.57% from the prior year.
• Cash & Current Investments climbed to $28.9 million in Q1 2026 per IMDX's latest filing, from $12.3 million in the prior quarter.
• The five-year high for Cash & Current Investments was $45.4 million in Q2 2022, with the low at $866000.0 in Q4 2022.
• Average Cash & Current Investments over 5 years is $17.4 million, with a median of $14.2 million recorded in 2023.
• Year-over-year, Cash & Current Investments tumbled 97.44% in 2022 and jumped 989.15% in 2023.
• Insight Molecular Diagnostics' Cash & Current Investments stood at $866000.0 in 2022, then jumped by 989.15% to $9.4 million in 2023, then dropped by 8.44% to $8.6 million in 2024, then soared by 42.57% to $12.3 million in 2025, then soared by 134.97% to $28.9 million in 2026.
• Business Quant data shows IMDX's Cash & Current Investments at $28.9 million in Q1 2026, $12.3 million in Q4 2025, and $19.4 million in Q3 2025.